CORCEPT THERAPEUTICS INC (CORT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $110.09, CORCEPT THERAPEUTICS INC (CORT) is priced for today's economics sustained for ~10.1 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/CORT

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.7% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: n/a

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=9)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 30.6%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Corcept sells one idea twice: block the cortisol receptor to treat hypercortisolism, and block the same receptor to make chemotherapy work better, the second of which the FDA approved in March 2026 as Lifyorli and which oncology guideline writers added to "Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a preferred regimen in April 2026".
• Selling and administrative expense reached $145.4 million in the three months to March 2026 against $90.7 million in the same quarter a year earlier, which pushed the quarter's operating result below break-even even though product revenue rose.
• Second-quarter results are scheduled for July 29, 2026 and will carry the first full quarter of Lifyorli selling, with the resubmitted hypercortisolism application, filed on June 17, 2026, the other decision still open.

Bull Case

A company with no funded borrowings and a repurchase authorization of 200 million dollars has an obvious way to spend money, and through 2025 Corcept used it. In the three months to March 2026 the buying stopped. Financing activities turned into a small net inflow of $0.8 million against a $39.8 million outflow in the same quarter a year before, and the money went into salespeople instead. That is management voting, in the only way that is hard to fake, that it thinks the return on selling a newly approved cancer drug beats the return on retiring its own stock.

What it is selling is one biological idea applied twice. Cortisol drives the signs of hypercortisolism, and blocking its receptor treats the disease. Cortisol also blunts the effect of chemotherapy, and blocking the same receptor may make chemotherapy work better. The 10-Q now defines the commercial franchise as Korlym, "our authorized generic of Korlym, and Lifyorli (collectively, our Products)", which is a quiet way of saying the company crossed from one market into a second one this spring. Lifyorli was approved in March 2026 in combination with nab-paclitaxel for platinum-resistant ovarian cancer, and Corcept began distributing it in April.

The guideline writers moved faster than launches usually allow. The regimen was added to "Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a preferred regimen in April 2026", which is not a sales forecast but does remove the reimbursement argument that normally eats a specialty launch's first year. Oncologists reach for the guideline before they reach for the rep.

Paying for that is possible because the older business throws off so much. The 10-Q reports product revenue of $164.9 million for the March quarter against $157.2 million a year earlier, carried on cost of sales of $2.9 million. Almost the entire top line survives the trip to the operating line before the company chooses what to spend it on. And the constraint on that older business has never been rivalry so much as recognition: "Because most people who suffer from hypercortisolism are undiagnosed or inadequately treated", which is why Corcept has spent years paying for screening and physician-education programs rather than for share-taking.

Set against the cohort, the spending looks less like a stumble than like a stage. NBIX runs $3.10B of trailing revenue at a 25.4% operating margin while still growing 28.6% a year, which is what a fully built specialty commercial organization eventually looks like. HRMY, closer to Corcept in size at $899.1M of revenue, holds a 21.1% operating margin while growing 20.7%. Neither reached that shape without paying for the sales force first. Corcept is paying for two of them at once, and it is doing so out of its own resources rather than by issuing stock. Management has also raised its own revenue guidance on 13 separate occasions since 2006 and cut it on one. That record says nothing about 2026, but it does describe a team that has generally known what its quarter looked like before it told anyone.

Bear Case

For most of its commercial life Corcept generated cash rather than consumed it, which is why it carries no funded borrowings and why the repurchase authorization in its filings was something it could genuinely afford. In the three months to March 2026 that reversed. Operating activities used $16.8 million against $4.8 million provided in the same quarter of 2025. Nothing here is fragile. But the property today's price leans on, a business that funds its own expansion, is precisely the property that just stopped holding.

That matters because of what the price asks for. At $95.30 the market is paying roughly 45 times what the business earns at the operating line across a full cycle, and a multiple that size only resolves if growth runs near the fastest pace the company could finance out of its own returns and stays there for about ten years. The rate is not the stretch. Corcept's recent pace sits inside what it has actually delivered. The stretch is the decade: of companies that reached that growth rate, roughly 14% were still running it ten years later. If the pace settles into something ordinary after five years instead of ten, the multiple does not survive the difference.

Meanwhile the demonstrated side of that comparison is under attack from a direction the quote does not obviously reflect. "Since January 2024, our Products also compete with a generic version of Korlym sold by Teva Pharmaceuticals", and the annual report lists among the things that could limit revenue "a lower-priced generic version of Korlym and off-label treatments". Look at the two lines that moved in the March quarter. Product revenue went from $157.2 million to $164.9 million. Selling and administrative expense went from $90.7 million to $145.4 million. One launch year explains that gap. A second one would start to describe the business rather than the moment.

The oncology approval also arrived on the heels of a reminder that the regulator is not a formality. "On December 30, 2025, the FDA issued a Complete Response Letter (CRL) declining to approve relacorilant" for hypercortisolism, which is the larger of the two opportunities and the one the existing sales organization is already built around. Corcept resubmitted in June 2026. A resubmission restarts a review; it does not settle one.

Underneath all of it sits litigation with an awkward subject. A qui tam suit brought in 2017 by a former employee concerns the sale and promotion of Korlym, and it is now proceeding without the government: the Department of Justice, the California Department of Insurance and the named Plaintiff States all declined to intervene, and the relator served an amended complaint on June 2, 2026. Declination is better news than intervention. It is not dismissal, and the questions a discovery process would ask about how the original product was sold land in the same year the commercial organization doubled.

None of the standard frames reach today's quote. The price sits roughly sixteen times above where the asset-value methods land, about nine times above the earnings-power methods, and about four times above where peer multiples come out. Even the forward-growth methods, the friendliest available and the only ones that get near, leave the price about 75% above them, and the one that gets closest does so by projecting revenue forward at roughly 12% a year and holding today's revenue multiple unchanged all the way to the end of the projection. The bear owes a concession here, and it is a real one: with $338.2 million in net cash, nothing owed, and a share count down about 2.4% a year across the four years to March 2026, Corcept can fund both launches without asking anyone for money. Survival is not the question. Whether the spending buys the ten years the price has already booked is.

Valuation

At $95.30, the price is not asking Corcept to be a good company. It is asking it to be a good company for a long time without interruption.

Strip the launch year out and the arithmetic reads like this. The market is paying roughly 45 times what the business earns at the operating line across a full cycle, and a multiple that size only closes if growth runs near the fastest pace the company could finance from its own returns and holds there for about ten years. The rate is inside what Corcept has recently delivered. The duration is the demanding part, and history is thin there: of the companies that reached that pace, about 14% were still running it a decade later.

Which figure that multiple sits on matters more than usual right now. The trailing twelve months ran slightly below break-even at the operating line, roughly -1.3% of revenue, because two commercial launches and a full research program were being funded at once. Measured on the company's own through-the-cycle economics instead, the operating margin is about 30.6%, and that is the figure the multiple above uses. The trailing number describes a decision, not an earning power.

None of the standard methods reach the quote, which is the cleanest fact in this section. The price sits roughly sixteen times above where the asset-value methods land, the ones that work from book equity and the return earned on it. It sits about nine times above the earnings-power methods, which capitalize what the company earns today and credit no growth whatever. Peer multiples come out about four times below it. Only the forward-growth methods get near, and the closest of them arrives by projecting revenue forward at roughly 12% a year and never letting today's revenue multiple compress across the whole projection; even then the price sits about 75% above where that family lands. Read plainly: every frame anchored on what Corcept has already done calls the stock dear, and the only frame that comes close is the one that books the next decade in advance.

The cohort gives the launch some context. HRMY, at $899.1M of revenue and a 21.1% operating margin, is roughly the size Corcept is now and is comfortably profitable at the operating line, because HRMY is not launching anything this year. ACAD carries $1.10B of revenue at a 7.4% operating margin. Corcept's own operating line is negative on trailing figures for a reason it chose, and the March quarter shows the choice in detail: the 10-Q reports selling, general and administrative expense of $145.4 million against $90.7 million a year earlier, and research and development of $66.3 million against $60.7 million.

None of that is a one-quarter artifact, and management says so directly: "We expect our selling, general and administrative expense to be higher in 2026 than in 2025". The reason it is affordable rather than dilutive is the balance sheet. Corcept holds $338.2 million in net cash, reports no funded borrowings, and has reduced its share count by about 2.4% a year over the four years to March 2026. That is what bounds the downside while the spending runs. It is not what buys the ten years.

Catalysts

Second-quarter results are scheduled for July 29, 2026. It is the first reporting period carrying a full quarter of Lifyorli, which the FDA approved in March 2026 and which Corcept began distributing in April. Two numbers will matter more than the headline: what the oncology line actually contributed in its first full quarter, and whether selling and administrative spending held near the March quarter's level or kept climbing.

The hypercortisolism application is back in front of the regulator. Corcept resubmitted its New Drug Application for relacorilant as a treatment for patients with Cushing's syndrome on June 17, 2026, after the agency declined to approve it at the end of 2025. A European marketing application covering the ovarian cancer combination is also outstanding, with the company's annual report pointing to a likely regulatory decision in the fourth quarter of 2026.

The legal calendar is the piece most easily overlooked. On May 19, 2026 the company learned that the Department of Justice had declined to intervene in a qui tam action filed in 2017 by a former employee concerning the sale and promotion of Korlym, and on June 2, 2026 the relator served an amended complaint. The suit now proceeds privately, which lowers the ceiling on the outcome without removing the discovery.

Peer Cohorts (Per Segment, With Filing Citations)

Corcept Therapeutics (consolidated) (reported)

• NBIX (NEUROCRINE BIOSCIENCES, INC.)
• FY2025 10-K: …in consolidation. Certain reclassifications have been made to previously reported amounts to conform to the current period presentation. Revenue Recognition We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we expect to receive in…
• FY2025 10-K: …and Abbott International Luxemburg S.a.r.l. Reference: Incorporated by reference to Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q filed on May 5, 2021 10.3* Description: Collaboration and License Agreement dated March 31, 2015 between Mitsubishi Tanabe Pharma Corporation and the Company Reference:…
• AXSM (AXSOME THERAPEUTICS, INC.)
• FY2025 10-K: …party, and Blackstone. This new direct agreement superseded the prior direct agreement among us, Antecip, a related party, and Hercules that had been entered into in connection with the Hercules Loan Agreement, which terminated automatically upon repayment of our Hercules loan obligations in full on May 8, 2025. F-…
• FY2025 10-K: …since the information required is included in the consolidated financial statements and notes thereto. Other schedules are omitted because they are not applicable, or the required information is shown in the Financial Statements or notes thereto. 3. Exhibits The list of exhibits filed with this report is set forth in…
• SUPN (SUPERNUS PHARMACEUTICALS, INC.)
• FY2025 10-K: …constraints are impacting our ability to fully meet this demand. ONAPGO is manufactured in Europe, supplied to us by our ONAPGO licensing partner, and packaged in the U.S. by a third-party contract manufacturing organization. We currently rely on single source suppliers to produce and package final dosage forms for…
• FY2025 10-K: …(NDA) for OSMOLEX ER. Acquisition of Sage Therapeutics, Inc. and Reorganization On June 13, 2025, the Company entered into an Agreement and Plan of Merger (Merger Agreement) to acquire Sage Therapeutics, Inc. (Sage). The acquisition closed on July 31, 2025. Sage was a pharmaceutical company with a portfolio of…
• HRMY (HARMONY BIOSCIENCES HOLDINGS, INC.)
• FY2025 10-K: …diseases segment consists of the Company's commercial product, WAKIX, and its potential product candidates, that focus on patients living with rare neurological diseases who have unmet needs. The Company currently derives all of its revenue from sales of WAKIX, which is used in the treatment of EDS and cataplexy in…
• FY2025 10-K: …territories, which are rights originally licensed from Teijin Pharma, the innovator of BP1.15205. We further broadened our portfolio into rare epilepsy when the Company acquired Epygenix Therapeutics, Inc. ("Epygenix") in April 2024. As a result, the Company now has an exclusive license relating to the use of…
• ACAD (ACADIA PHARMACEUTICALS INC)
• FY2025 10-K: …and delusions associated with PDP. NUPLAZID became available for prescription in the United States in May 2016. In March 2023, the FDA approved the Company's second drug, DAYBUE ® (trofinetide), for the treatment of Rett syndrome. DAYBUE became available for prescription in the United States in April 2023. In October…
• FY2025 10-K: …any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. F- 1 Medicare Part D sales rebate accruals Description of…
• ALKS (Alkermes plc.)
• FY2025 10-K: …Agreement were released in connection with the termination. Such prepayment was accounted for as a debt extinguishment. See Note 11, Long-Term Debt , in the "Notes to Consolidated Financial Statements" in this Annual Report for additional discussion related to our Former Term Loans. Discontinued Operations Net loss…
• FY2025 10-K: …TECFIDERA (dimethyl fumarate), and PLEGRIDY (peginterferon beta-1a) from Biogen; OCREVUS (ocrelizumab) from Genentech; BETASERON (interferon beta-1b) from Bayer HealthCare Pharmaceuticals; COPAXONE (glatiramer acetate) from Teva; REBIF (interferon beta-1a) and MAVENCLAD (cladribine) from EMD Serono, Inc.; GILENYA…
• APLS (APELLIS PHARMACEUTICALS, INC.)
• FY2025 10-K: …bias. o We held discussions with financial and operational management to determine whether any strategic, regulatory, or operational changes in the business were consistent with the projections of future demand that were utilized in estimating the provision recorded. • We tested the effectiveness of controls over…
• FY2025 10-K: …Public Accounting Firm (PCAOB ID: 34) 110 Consolidated Financial Statements as of and for the years ended December 31, 2024 and 2023 and for each of the three years in the period ended December 31, 2024: Consolidated Balance Sheets as of December 31, 2025 and 2024 112 Consolidated Statements of Operations and…
• FOLD (AMICUS THERAPEUTICS, INC.)
• FY2025 10-K: …To Consolidated Financial Statements 1. Description of Business Amicus Therapeutics, Inc. (the "Company") is a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases. With extraordinary patient focus, Amicus…
• FY2025 10-K: …its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit and Compliance Committee at its next scheduled meeting. -166- Table of Contents -167- Table of Contents PART IV Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULE 1. Index to…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.